Pamrevlumab, a Fully Human Monoclonal Antibody Targeting Connective Tissue Growth Factor, for Non-Ambulatory Patients with Duchenne Muscular Dystrophy.

Connolly, Anne M; Zaidman, Craig M; Brandsema, John F; Phan, Han C; Tian, Cuixia; Zhang, Xueping; Li, Jack; Eisner, Mark D; Carrier, Ewa

Connolly, Anne M; Zaidman, Craig M; Brandsema, John F; Phan, Han C; Tian, Cuixia; Zhang, Xueping; Li, Jack; Eisner, Mark D; Carrier, Ewa.

Afiliação

Connolly AM; Nationwide Children's Hospital, Ohio State University College of Medicine, Columbus, OH, USA.
Zaidman CM; Department of Neurology, Washington University at St. Louis, St. Louis, MO, USA.
Brandsema JF; Division of Neurology, The Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Phan HC; Rare Disease Research, LLC, Atlanta, GA, USA.
Tian C; Division of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Zhang X; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Li J; FibroGen, Inc., San Francisco, CA, USA.
Eisner MD; FibroGen, Inc., San Francisco, CA, USA.
Carrier E; FibroGen, Inc., San Francisco, CA, USA.

J Neuromuscul Dis ; 10(4): 685-699, 2023.

Article em En | MEDLINE | ID: mdl-37248912

Assuntos

Distrofia Muscular de Duchenne; Humanos; Distrofia Muscular de Duchenne/genética; Distrofina; Anticorpos Monoclonais/uso terapêutico; Fator de Crescimento do Tecido Conjuntivo

Palavras-chave

Clinical trial; Duchenne muscular dystrophy; connective tissue growth factor; grip strength; monoclonal antibody; pamrevlumab; percent predicted forced vital capacity

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Distrofia Muscular de Duchenne Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google